EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC

Inclusion Criteria:

• Patients who was confirmed non-small cell lung cancer (NSCLC) by histology orcytology, harboring EGFR mutant type (19 and/or 21 exon mutation).

• Patients who was confirmed with asymptomatic, treatment naive brain metastasis (didn'treceive any treatment after diagnosed with brain metastasis) by MRI, couldn't receiveoperation or stereotactic radiosurgery（SRS）.

• Appraisable disease, that is there must be at least one lesion with the longestdiameter>10mm in brain (by brain MRI).

• Adult patients (18 to 75 years old). Eastern Cooperative Oncology Group（ECOG）performance status 0 to 2. Life expectancy of at least 12 weeks. Haemoglobin > 10g/dl,absolute neutrophil count (ANC) > 1.5 x 10^9/L, platelets > 100 x 10^9/L; totalbilirubin < 1.5x upper limit of normal (ULN). Alanine aminotransferase（ALT） andaspartate aminotransferase（AST）< 1.5x ULN in the absence of liver metastases, or < 5xULN in case of liver metastases. Creatinine clearance > 60ml/min (calculated accordingto Cockcroft-gault formula).

• Patients should be contraceptive during the period of the trial.

Exclusion Criteria:

• Patients who had received brain radiotherapy or EGFR-TKI before.

• Patients who can't receive WBRT.

• Uncontrolled intracranial hypertension after steroid or dehydration therapy.

• Patients who take phenytoin, Carbamazepine, Rifampicin, Barbital, or St John's Wortwhich will interfere with the metabolism of TKI.

• Patients with interstitial lung disease, significant ocular disease, or seriousuncontrolled systematic disease.

• Patients who can't take oral tablets, with active peptic ulcer diseases.

• Pregnancy or breast-feeding women.